The purpose of the study is to see whether lunsekimig can reduce the number of moderate to severe flare‑ups of the lung disease over a year. After enrollment, participants will be randomly assigned to one of the two groups and will attend regular clinic visits for injections, safety checks, and simple breathing tests over several months.

A flare‑up, or exacerbation, means a sudden worsening of breathing problems that often requires extra medication or a hospital visit. The term Forced Expiratory Volume in 1 second refers to a common breathing test that measures how much air a person can force out of their lungs in one second; it helps doctors track lung function. The eosinophilic pattern is identified by a blood test that shows higher eosinophil counts, which can influence how the disease behaves and responds to treatment.

Participants in the study will be randomly assigned to one of the two treatment groups. The treatments will be given through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. The study will monitor how long patients live without their cancer getting worse, as well as their overall survival. The study will also look at how well the cancer responds to the treatment and how long any positive effects last.

The study aims to provide important information about the effectiveness of these treatment combinations for patients with advanced NSCLC. By comparing these treatments, researchers hope to find the best option for managing this type of lung cancer. The study will continue for several years to gather enough data to make informed conclusions about the treatments’ benefits and safety.

The trial will compare the effects of Clazakizumab with a placebo, which is a substance that looks like the medication but does not contain the active ingredient. The study will also use a saline solution, which is a simple saltwater solution, as part of the trial process. The purpose of the study is to determine the best dose of Clazakizumab that can effectively reduce inflammation and to assess its safety in patients with ESKD. Participants will receive the medication or placebo through an intravenous injection, which means it is given directly into a vein.

Throughout the study, researchers will monitor the participants’ health and track any changes in their condition. The study will also look at the impact of Clazakizumab on cardiovascular health, which refers to the health of the heart and blood vessels. This is important because patients with ESKD are at a higher risk of developing heart-related issues. The trial is designed to provide valuable information on how Clazakizumab can help manage inflammation and improve overall health outcomes for patients with ESKD undergoing dialysis.

After the surgery, each person receives the assigned injection—either under the skin (subcutaneous) or into a muscle (intramuscular)—on a schedule set by the study team. Follow‑up visits are planned regularly to check health, monitor any side effects, and assess overall well‑being.

During the study, doctors will watch for any adverse events (unwanted health problems) and ask participants to complete questionnaires about their quality of life and daily functioning. This information helps determine if the treatment is safe and if it improves outcomes compared with the control injection.

The main aim of the study is to see whether this new regimen works better and is safe compared with the usual care for these cancers.

Participants will receive the study medicines in repeated treatment cycles, each lasting a few weeks, with regular check‑ups to monitor tumor size and overall health. Tumor changes are measured using standard imaging and a set of rules called RECIST 1.1. The study looks at how long patients live without the cancer getting worse, known as PFS, and how long patients live overall, referred to as OS. Blood tests and heart checks are done throughout to watch for side effects.

The purpose of the study is to find out whether the new medicine can improve breathing and reduce serious flare‑ups compared with the placebo. People who join will be randomly assigned to one of the two groups, and neither the participants nor the study staff will know which treatment each person receives (double‑blind). Over several months, participants will come to the clinic for routine visits where their lung function, symptoms and overall health will be checked.

During the study, participants will receive the injections at set intervals and will have simple breathing tests, such as measuring forced expiratory volume in one second (FEV1), which shows how much air can be exhaled quickly. They will also answer short questionnaires about how they feel, and will have basic safety checks like blood tests and a quick heart rhythm check (ECG). All of this information helps researchers see if the medicine works and is safe.

During the study, participants will be assigned to receive either depemokimab or a placebo through a subcutaneous injection, which is a shot given just under the skin. The study is designed so that neither the participants nor the researchers know which treatment is being administered. This approach helps ensure that the results are as accurate as possible.

The purpose of the trial is to determine whether MK-8748 is at least as effective as aflibercept in preserving or improving vision. Participants will receive a series of injections into the eye over the course of about one year, with regular visits for eye checks, vision testing, and imaging that may involve the fluorescein dye.

Vision is measured using best-corrected visual acuity, which is the sharpest vision possible with the best glasses or contacts, and the results are recorded as letters on an ETDRS chart, a standard eye‑test chart. Throughout the study, doctors will monitor participants for any side effects or safety concerns.

Participants in the study will receive either Dupilumab, which is administered as a solution for injection in a pre-filled syringe, or a matched placebo. The purpose of the study is to see if Dupilumab can significantly reduce the itchiness of LSC over a period of 24 weeks. The study will monitor changes in the severity of itching and its impact on sleep and quality of life. Additionally, the study will track any side effects or adverse reactions to the treatment.

The trial is designed to be a randomized, double-blind, placebo-controlled study, meaning neither the participants nor the researchers will know who is receiving Dupilumab or the placebo. This approach helps ensure the results are unbiased. The study will last for approximately 24 weeks, during which participants will be regularly assessed to measure the effectiveness of the treatment and any changes in their condition.

The purpose of the study is to assess how effective and safe sonelokimab is for adults with moderate to severe hidradenitis suppurativa. Participants in the study will receive either sonelokimab or a placebo over a period of 16 weeks. During this time, researchers will monitor the participants to see if there is a 75% improvement in their condition, which is measured by a specific score called the Hidradenitis Suppurativa Clinical Response (HiSCR) score. The study will also track any side effects or adverse events that occur during the treatment period.

Throughout the study, participants will undergo regular check-ups, including physical examinations and laboratory tests, to ensure their safety and to gather data on the treatment’s effects. The trial aims to provide valuable information on whether sonelokimab can be a beneficial treatment option for those suffering from hidradenitis suppurativa, potentially improving their quality of life by reducing the severity of their symptoms.

Participants in the study will be randomly assigned to receive either Upadacitinib or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations. The study will last for a period of time, during which participants will take the medication orally in the form of a modified-release tablet. The goal is to observe any changes in the severity of eczema symptoms and overall skin condition over the course of the study.

Throughout the study, participants will be monitored for any improvements in their eczema symptoms, such as reduced itching and inflammation, as well as any potential side effects. The study aims to provide valuable information on whether Upadacitinib can be an effective treatment option for those suffering from moderate to severe eczema. By participating in this study, researchers hope to gain insights that could lead to better management and treatment options for individuals with this challenging skin condition.

The purpose of the study is to see whether oral semaglutide can help slow worsening of memory, thinking, and daily function in people with early Alzheimer’s disease, and to check its safety. The study is randomised, which means the treatment is assigned by chance, and double-blind, which means neither the participants nor the study team knows who receives semaglutide or placebo during the study. Treatment is taken by mouth over a long period, and the study follows changes over time.

Participants take the study tablets regularly and are seen at planned visits during the trial. These visits are used to monitor health, review how the person is doing, and record any changes in memory, daily activities, or side effects. The study compares how people do over time in the semaglutide and placebo groups.

People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

The purpose of the study is to evaluate the long‑term safety and tolerability of the medication. Over several months, participants will take the drug each day and attend regular clinic visits where doctors will check blood work (laboratory tests that look at how the body is functioning), perform an ECG (a quick test that records the heart’s electrical activity), measure vital signs such as blood pressure and weight, and conduct simple memory and thinking assessments to see how cognition changes.

Throughout the trial, any side effects or new health problems will be recorded, and participants may stop the medication if serious issues arise. The overall goal is to determine whether the drug can be used safely for people living with this condition.

People in the study will receive either VMX-C001 or the usual care used for this situation. Some participants may also receive heparin, another blood-thinning medicine, if planned by the treating team. The study is designed to compare the two approaches during the procedure and shortly afterward, without changing the urgent care needed for the surgery or procedure.

The study is a follow-up, or extension, of earlier research and is designed to continue for a long period. During the study, participants will take the study tablets and return for regular checkups so the study team can watch for any health problems and see how the treatment is being tolerated over time. The study compares the two remibrutinib doses with placebo in a blinded way, which means the treatment given is not revealed to the participants or the study team during the study.

The study is a Phase 3 trial, which means it is being done in a larger group of people to better understand how well the treatment works and how safe it is. People taking part are assigned by chance to receive either nipocalimab or placebo. The treatment is given over time, and the study team follows participants through the treatment period to observe how the disease changes.

The purpose of this research is to determine how well ruxolitinib cream works in treating moderate atopic dermatitis in young patients. During the study, participants will apply either ruxolitinib cream or the vehicle cream to affected areas of their skin, excluding the scalp. The treatment period lasts for 8 weeks, followed by an extended observation period.

The study will monitor changes in skin condition, including improvements in rash coverage, intensity of itching, and overall disease severity. Blood samples will be collected from some participants to measure how much of the medication enters the bloodstream. The research will also track any side effects that may occur during the treatment period.

The purpose of this research is to evaluate how well different doses of Rocatinlimab work compared to placebo in reducing itching in people with Prurigo Nodularis. The medication will be given as a subcutaneous injection (an injection under the skin). The study will last for 52 weeks, during which participants will receive either Rocatinlimab or placebo.

Throughout the study, participants will need to keep a daily record of their symptoms, including itching intensity and skin pain. Doctors will regularly examine the skin nodules and monitor how the treatment affects participants’ quality of life and sleep. The study will also track any side effects that may occur during the treatment period.

The main goal is to assess the long‑term safety and tolerability of the medicine, meaning researchers will watch for any side effects or problems over an extended period. After the initial treatment period, participants will continue to attend regular visits where doctors will ask about health changes, perform a simple nasal examination, and may take a small blood sample to check drug levels. The study also records whether participants need additional treatments such as a short course of a systemic corticosteroid (a pill that reduces inflammation throughout the body) or sinus surgery.

The purpose of the study is to see how effective and safe these treatments are for patients with this type of lung cancer. Participants will receive either rilvegostomig or pembrolizumab, along with chemotherapy drugs such as carboplatin and paclitaxel. The study will monitor how long patients live and how long they remain free from cancer progression, which means the cancer does not get worse. The study will also look at other factors like the overall response to the treatment and any side effects experienced.

Participants will receive their treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will take place over several months, and participants will have regular check-ups to monitor their health and the effects of the treatment. The goal is to find out which combination of treatments works best for this type of lung cancer.

The study follows people for a long period and looks at whether normal thyroid function can be kept after treatment has been stopped. During the study, adults receive the study medicine and are then observed over time to see whether thyroid levels remain stable without ATD (anti-thyroid drugs, medicines that lower thyroid hormone). Some participants may stop the study medicine earlier or later than others as part of the study plan. The study also checks whether TRAb (thyroid-stimulating hormone receptor antibodies, proteins made by the immune system that can affect the thyroid) are no longer found in the blood.

The study is designed as a long-term extension, meaning it continues to follow people who have already taken part in earlier research with this medicine. Information is collected over many months, with the main follow-up lasting up to 52 weeks after treatment changes. The study uses groups of participants to compare how long thyroid control lasts after stopping treatment and how often the disease returns, also called a relapse.

The study will compare FWY003 with placebo in people with this eye condition. It is a randomized study, which means the treatment is assigned by chance, and double masked, which means neither the participants nor the study team know who receives FWY003 or placebo during the study. Over time, the study follows changes in the damaged area in the eye and also watches for side effects and other health changes. The study lasts for many months and includes regular visits during which eye health and general well-being are reviewed.

Adults who have had a kidney transplant are assigned to one of the study treatments. The study is randomized, which means the treatment is chosen by chance, and open-label, which means the treatment is known to the doctors and the participants. Frexalimab is given as an injection, while tacrolimus is taken by mouth as a capsule. The study follows participants for several years after transplantation to observe how the kidney is doing and to watch for signs of rejection, graft loss, death, and side effects.

During the study, regular checkups are done to monitor kidney function, general health, and possible unwanted effects of treatment. The study also looks at new health problems that can happen after a transplant, such as high blood pressure, abnormal blood fats, and diabetes. eGFR is one of the kidney tests used in the study; it is an estimate of how well the kidney is filtering the blood.

The study is planned to last about 50 weeks for each person. During the study, treatment is given at regular times, and health checks are done over the course of the trial to watch for side effects and other changes in health. The study also looks at lung function, which means how well the lungs move air in and out.

The purpose of this study is to see how effective Plozasiran is at reducing triglyceride levels in people with severe hypertriglyceridemia. Participants in the study will receive either Plozasiran or a placebo and will be monitored over a period of 12 months. During this time, the study will measure changes in triglyceride levels and monitor for any side effects. The goal is to determine if Plozasiran can significantly lower triglyceride levels compared to the placebo.

Participants will receive regular injections and attend scheduled visits to track their progress. The study aims to provide valuable information on the safety and effectiveness of Plozasiran, which could lead to new treatment options for people with severe hypertriglyceridemia. This research is important for understanding how to better manage this condition and improve patient outcomes.

The purpose of the study is to evaluate how well AVP-786 works in reducing agitation symptoms in patients with Alzheimer’s-related dementia. Participants in the study will receive either the AVP-786 medication or a placebo. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will take the medication in capsule form by mouth. The study will last for a set period, during which participants will be monitored for any changes in their symptoms and any side effects they may experience. The goal is to determine if AVP-786 can help manage agitation in patients with Alzheimer’s-related dementia more effectively than a placebo.

Participants in the study will receive Batoclimab through a subcutaneous injection, which means it is injected under the skin. The treatment will be administered once a week for a total of 24 weeks. For the first 12 weeks, participants will receive a dose of 680 mg, followed by a reduced dose of 340 mg for the remaining 12 weeks. Some participants will receive a placebo, which looks like the treatment but does not contain the active substance.

The study aims to observe changes in the condition of the eyes, specifically looking at the reduction in eye protrusion, known as proptosis, by the end of the 24-week period. The trial will also monitor other aspects of the disease, such as changes in eye inflammation and overall eye health. The goal is to determine if Batoclimab can effectively improve symptoms of TED compared to the placebo.

The study is divided into two stages. In the first stage, researchers will determine the best dosing schedule for the eye drops. In the second stage, they will compare the effects of the eye drops to a placebo over a period of 52 weeks. Participants will be randomly assigned to receive either the OCS-01 eye drops or a placebo, and neither the participants nor the researchers will know which treatment each participant is receiving. This is known as a “double-masked” study, which helps ensure that the results are unbiased.

Throughout the study, participants will have regular check-ups to monitor their eye health and vision. The main focus will be on changes in vision clarity, measured by a test called Best Corrected Visual Acuity (BCVA). This test helps determine how well a person can see with the best possible glasses or contact lenses. The study aims to see if the OCS-01 eye drops can improve vision in people with DME compared to those who receive a placebo. Participants will also be monitored for any side effects or safety concerns related to the treatment.

Participants in the study will receive either eneboparatide or a placebo for a period of 24 weeks. The treatment is administered through a pre-filled pen for subcutaneous injection, which means it is injected under the skin. The goal is to evaluate how effective eneboparatide is in reducing the need for active vitamin D and oral calcium supplements, and in maintaining normal serum calcium levels. The study will also assess changes in symptoms and physical functioning of the participants.

In addition to eneboparatide, the study involves other medications such as calcitriol and calcium carbonate, which are commonly used to manage calcium levels. Another medication, alfacalcidol, is also part of the study. These medications are used to help understand the overall effectiveness of the new treatment. The study aims to provide valuable information on the safety and benefits of eneboparatide for people living with chronic hypoparathyroidism.

The purpose of this study is to determine if deucravacitinib is more effective than a placebo in treating people with active SLE. Participants in the study will be randomly assigned to receive either deucravacitinib or a placebo. The study will last for a period of 52 weeks, during which participants will be monitored for their response to the treatment. The main goal is to see how many participants achieve a significant improvement in their SLE symptoms by the end of the study period.

Throughout the study, participants will be assessed for changes in their condition, including improvements in joint pain, skin rashes, and overall disease activity. The study will also track any side effects or adverse events that may occur. By the end of the study, researchers hope to gather valuable information on the potential benefits and risks of using deucravacitinib for treating SLE, which could lead to better treatment options for those affected by this condition.

Participants will be assigned to receive either clemizole hydrochloride in the form of an oral solution or a placebo. The study is designed as a double-blind trial, meaning that neither the participants nor the researchers will know which substance is being administered during the process. The course of the study involves different stages, including a period where the dose is gradually adjusted, followed by a maintenance period where the treatment is continued.